Evaluation of cardiovascular risk in patients with Parkinson disease under levodopa treatment

BACKGROUND: Levodopa is the indispensable choice of medial therapy in patients with Parkinson disease (PD). Since L-dopa treatment was shown to increase serum homocysteine levels, a well-known risk factor for cardiovascular disorders, the patients with PD under L-dopa treatment will be at increased...

Descripción completa

Detalles Bibliográficos
Autores principales: Günaydın, Zeki Yüksel, Özer, Fahriye Feriha, Karagöz, Ahmet, Bektaş, Osman, Karataş, Mehmet Baran, Vural, Aslı, Bayramoğlu, Adil, Çelik, Abdullah, Yaman, Mehmet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Science Press 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4753016/
https://www.ncbi.nlm.nih.gov/pubmed/26918017
http://dx.doi.org/10.11909/j.issn.1671-5411.2016.01.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4753016/
https://www.ncbi.nlm.nih.gov/pubmed/26918017
http://dx.doi.org/10.11909/j.issn.1671-5411.2016.01.003

Ejemplares similares